Company: OFIX
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026066
Chunk: 223

Company: Orthofix Medical Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 223
---
 loss. The Company adopted this standard effective January 1, 2024, on a prospective basis. Refer to Note 16 for the Company's updated business segment disclosures.

F-10

Recently Issued Accounting Pronouncements

        Topic
         
        Description of Guidance
         
        Effective Date
         
        Status of Company's Evaluation

        Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (ASU 2023-06)
         
        Adds interim and annual disclosure requirements to a variety of subtopics in the Accounting Standards Codification, including those focusing on accounting changes, earnings per share, debt, and repurchase agreements. The guidance will be applied prospectively. The effective date will be the date when the SEC's removal of the related disclosure requirement becomes effective, with early adoption prohibited.
         
        Various
         
        The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.

        Improvements to Income Tax Disclosures (ASU 2023-09)
         
        Enhances the transparency and decision-making usefulness of income tax disclosures to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The amendments are to be applied prospectively, but retrospective application is permitted.
         
        January 1, 2025
         
        The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.

        Disaggregation of Income Statement Expenses (ASU 2024-03)
         
        Improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the note to the financial statements at interim and annual reporting periods. The amendments are to be applied prospectively to financial statements issued and retrospectively to all prior periods presented in the financial statements.
         
        January 1, 2027
         
        The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.
       
      Other recently issued ASUs, excluding those ASUs which have already been disclosed as adopted or described above, were assessed and determined not applicable, or are expected to have minimal impact on the Company's consolidated financial statements.

4.	Mergers and acquisitionsMerger with SeaSpineOn January 5, 2023, the Company and SeaSpine completed an all-stock merger of equals (the "Merger") to create a global medical technology company that provides medical technologies that